Hypertension and hyperkalaemia responding to bendrofluazide.
A 33-year-old man is described with hyperkalaemia, hypertension and acidosis. The blood pressure was 160 to 200 mmHg systolic and 90 to 110 mmHg diastolic and the plasma potassium was between 6.0 and 7.0 mmole per litre. There was no renal disease and creatinine clearance was 103 ml per minute. Plasma renin activity was low and plasma aldosterone was at the lower limit of normal. Sodium deprivation or oral frusemide had little effect on blood pressure, plasma potassium, renin, aldosterone or arginine vasopressin. However, bendrofluazide caused a rapid fall of blood pressure and plasma potassium, and rise of plasma renin, aldosterone and plasma arginine vasopressin. Hypertension and hyperkalaemia is rare in the absence of renal failure. Four similar patients reported previously are reviewed. We suggest that our patient, and perhaps some of those reported earlier had primary abnormality of renal tubular function with impaired secretion of potassium and excessive tubular reabsorption of sodium. The plasma renin activity could be due to volume expansion and the low plasma aldosterone was probably caused by the antagonistic effects of low renin depressing synthesis and hyperkalaemia increasing it. A minor similar tubular abnormality might be the explanation in some of the patients with essential hypertension who have low plasma renin activity.
D000328:Adult; D000450:Aldosterone / Q000097:blood; D001127:Arginine Vasopressin / Q000097:blood; D001539:Bendroflumethiazide / Q000627:therapeutic use*; D004039:Diet, Sodium-Restricted; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D006947:Hyperkalemia / Q000097:blood / Q000150:complications* / Q000628:therapy; D006973:Hypertension / Q000097:blood / Q000150:complications* / Q000628:therapy; D008297:Male; D011188:Potassium / Q000097:blood; D012083:Renin / Q000097:blood
D001127:Arginine Vasopressin; D000450:Aldosterone; D001539:Bendroflumethiazide; D005665:Furosemide; D012083:Renin; D011188:Potassium